Antonio Iñesta. Blog Web2.0 y Salud http://fecoainesta.blogspot.com.es/
Esta es la quinta
parte del Índice de los Blogs publicados en 2025.
*Medicamentos contra el Cáncer
aprobados en 2025
*Índice principios activos de los MED contra el Cáncer aprobados en 2025
*Clasificación y Nombre comercial de los MED contra el Cáncer aprobados en
2025
*Medicamentos contra el Cáncer por Indicaciones, en 2025
*Medicamentos
contra el Cáncer que pronto estarán comercializados
*Pruebas de diagnóstico acompañante de los MED contra el Cáncer aprobados
en 2025
*Medicamentos contra el Cáncer que
pronto estarán comercializados 2025
Cáncer, EEUU, España, Inmunoterapia,
Medicamentos, Salud, Tramite de registro, Unión Europea.
New Drug
Application (NDA, Solicitud de nuevo medicamento); supplemental NDA (sNDA, Solicitud de nuevo
medicamento complementaria); Biologics License Application (BLA, Solicitud de licencia de productos
biológicos); supplemental
BLA (sBLA, Solicitud de licencia de productos biológicos complementaria); Rare
Pediatric Disease designation (RPDD); Regenerative Medicine
Advanced Therapy; presentación
de NDA o de BLA a la FDA; Investigational
NDA; Fast Track (Vía rápida); Breakthrough Therapy
(Terapia innovadora); Priority
Review (Revisión prioritaria). Resaltado
en el nombre
comercial significa Comercializado no con las mismas indicaciones; alo = alogénico, que procede de otro
individuo de la misma especie del que lo recibe.
- 4A10 (Allterum Therapeutics),
Blog 3/12/2025; 7MW4911
(Mabwell) (ADCanti topoisomerasaADN), Blog
3/09/2025;
- Abenacianina para inyección
(Vergent Bioscience), Blog 3/02/2025; ABT-301 (ver Imofinostat),
Blog 3/09/2025; ADCE-T02 (AMT 754, Adcendo
ApS)(ADCanti TF), Blogs: 3/11/2025, 3/03/2025; ADRX-0706 (Adcentrx Therapeutics)(ADCanti
Nectina-4), Blog 3/06/2025; AKY-1189 (Actinio (Ac-225) AKY 1189, Aktis
Oncology) (Radiofármaco), Blog 3/06/2025; Alnodesertib (University of
Oklahoma) e irinotecan, Blog 3/12/2025; ALX2004 (ALX Oncology Holdings Inc.)(ADCanti EGFR),
Blog 4/05/2025; Amezalpat (Tempest
Therapeutics)(Inh PPARα), Blog 3/03/2025; Ateganosina (6-thio-2’-deoxyguanosine, MAIA
Biotechnology)(Inh Telomerasa), Blog
3/08/2025; AUTX-703 (Auron Therapeutics) (Degradador KAT2A), Blog
3/03/2025; Avutometinib
y defactinib ((Avmapki
Fakzynja Co-pack, Verastem, Inc.), Blog 3/02/2025, aprobado Blog 1/06/2025; AVZO-103 (Avenzo Therapeutics)(Inh DNA topoisomerase I), Blog
3/12/2025; AVZO-1418 (Duality Biotherapeutics)(ADCanti EFGR/HER3), Blogs: 3/12/2025, 3/06/2025;
Azercabtagén zapreleucel
(azer-cel; Imugene)(alogCarTAnti CD19), Blog 3/04/2025;
- BBO-8520 (BridgeBio Oncology
Therapeutics)(5.Inh KRAS), Blog
3/02/2025; BCB-276 (BrainChild Bio, Inc.)(CarTAnti B7-H3), Blog 4/05/2025; Belzutifan (Welireg, Merck; FDA)(Inh HIF-2alfa), aprobado Blog 3/02/2025,
Blog 1/06/2025; BGB-B2033
(BeOne Medicines)(AcMB GPC3/4-1BB), Blog 31/12/2025; Birelentinib (DZD8586, Dizal)(2.2.Inh BTK/LYN),
Blog 3/09/2025;
- CBI-1214 (Cartography
Biosciences), Blog 31/12/2025; CER-1236
(CERo Therapeutics Holdings, Inc.)(CarTAnti Tim-4L), Blogs: 3/10/2025, 4/05/2025; CLD-201 (SuperNova, Calidi Biotherapeutics Inc.)(Inmunoestimulantes),
Blogs: 3/08/2025, 4/05/2025; CLN-049
(Cullinan Therapeutics)(AcMB FLT3/CD3), Blog 31/12/2025; Cobre (Cu-64) SAR-bisPSMA
(Clarity Pharmaceuticals)(Radiofármacos), Blog
3/02/2025; Cobre
(Cu-67) SAR-bisPSMA (67Cu-SAR-bisPSMA, Clarity Pharmaceuticals)(Radiofármacos), Blog 3/03/2025; CRB-701 (Corbus
Pharmaceuticals), Blog 3/10/2025; CTD402 (Bioheng Therapeutics US LLC)(alogCarTanti
CD7), Blog 3/04/2025; CUSP06 (OnCusp
Therapeutics, Inc.)(ADCanti CDH6), Blog 3/03/2025;
- Damo Panda (CTOL Digital Solutions)(Int Artific), Blog 4/05/2025; Daraxonrasib (Revolution Medicines, Inc.)(5.Inh
KRAS/G12C), Blog 3/08/2025; Darovasertib (Ideaya Biosciences, Inc.)(3.9.Inh
PKC), Blogs: 4/05/2025, 3/04/2025; Datopotamab deruxtecan (Datroway,
Daiichi-Sankyo)(ADCanti TROP2), Blog 3/02/2025, aprobado Blog 1/07/2025; DCISionRT test (PreludeDx)(Test), Blog
3/02/2025; Detalimogén voraplásmido (enGene Holdings Inc.)(Ter Gén&Cel), Blog
3/07/2025; Dordaviprona (Modeyso, Jazz
Pharmaceuticals, Inc.)(Activador de proteasa), Blog 3/03/2025, aprobado Blog 1/09/2025; DPTX3186 (Dewpoint Therapeutics), Blog 3/12/2025; Durvalumab (Imfinzi, AstraZeneca; FDA, EMA, España
UH)(Anti PD-L1), Blog 3/08/2025;
- EBC-129 (Experimental Drug Development Centre) (ADCanti CEACAM5/6), Blog
3/06/2025; Enfortumab
vedotina (Padcev, Astellas Pharma US; FDA (-ejfv), EMA, España UH)(ADCanti Nectina4) con pembrolizumab
(Keytruda), Blog 3/11/2025; EO2463
(BioSpace), Blog 3/11/2025; ETX-636
(Ensem Therapeutics)(3.4.Inh PI3Kα), Blog 3/11/2025; EVM14 (Everest Medicines)(Vac ARNm), Blog 3/04/2025; EvoLiver test (Mursla Bio)(Test), Blog 4/05/2025;
- Ficerafusp alfa (Bicara
Therapeutics)(AcMB EGFR/TGFβ), Blog
3/11/2025; FOG-001 (Parabilis
Medicines)(Inh β-catenin/TCF4), Blog 3/12/2025;
- Galio (Ga 68) DPI-4452 (ITM Isotope Technologies Munich SE)(Radiofármacos), Blog 3/12/2025; Gemogenovatucel-T (Vigil, Gradalis, Inc.)(Ter Gén&Cel), Blog 3/03/2025; Givinostat (Italfarmaco)(Inh HDAC), Blog 3/06/2025; GL-IL2-138 (Genetic Leap)(Modulator IL2), Blog 3/08/2025; GLIX1 (Hemispherian)(Estim TET2), Blog 3/09/2025; GLPG5101 (Galapagos NV)(CAR-T cell therapies), Blog 3/09/2025; GLSI-100 (Greenwich LifeSciences)(Vac HER2/Neu GP2), Blog 3/10/2025; GSK5764227 (GSK’227, GSK plc)(ADCanti B7-H3), Blog 3/02/2025;
- Haystack MRD test (Quest
Diagnostics)(Test), Blog 3/09/2025; HLD-0915 (Halda Therapeutics)(Inh BRD4), Blog 3/09/2025;
- IBI363 (Innovent Biologics)(AcMB PD-1/IL-2α),
Blog 3/03/2025; IDE849 (SHR-4849, Ideaya
Biosciences)(ADCanti DLL3/TOP1), Blog 3/06/2025; Ifinatamab deruxtecan (I-DXd, Merck)(ADCanti
B7-H3), Blog 3/09/2025; Iltamiocel (UC Davis Health)(Ter Gén&Cel), Blog
4/05/2025; Imofinostat (ABT-301, Anbogen Therapeutics)(Inh HDAC), Blog
3/09/2025; Invikafusp
alfa (Marengo Therapeutics, Inc.)(TCR Bispecific
antibodies IL-2), Blog 3/02/2025; INX-315 (Incyclix Bio)(3.7.Inh CDK2), Blog 3/06/2025; ISB 2001 (Ichnos Glenmark Innovation)(AcMTri
BCMA-CD38/CD3), Blog 3/06/2025; IsoPSA test (Cleveland Diagnostics, Inc)(test), Blog 31/12/2025; Izalontamab brengitecan (iza-bren,
SystImmune Inc. & Bristol Myers Squibb)(ADCanti EGFR/HER3), Blog 3/09/2025;
- JSKN003 (Alphamab Oncology)(ADCanti HER2/HER2), Blogs:
31/12/2025, 3/11/2025;
- Lacutamab (Innate Pharma)(Anti KIR3DL2), Blog
3/12/2025; Leronlimab (CytoDyn)(Anti
CCR5), Blog 3/04/2025; Letetresgén autoleucel (lete-cel,
Adaptimmune Therapeutics plc.)(TCR-TAnti NY-ESO-1), Blog 3/02/2025; Linperlisib, (Shanghai Yingli Pharmaceutical Co.,
Ltd.)(3.4.Inh PI3K), Blog 4/05/2025; Linvoseltamab (Lynozyfic, Regeneron Pharmaceuticals, Inc.)(AcMB
BCMA/CD3), Blog 3/03/2025, aprobado
Blog 1/08/2025; Lisocabtagén maraleucel
(liso-cel; Breyanzi,
Bristol Myers Squibb; FDA, EMA, España autorizado no comercializado)(CarTAnti
CD19), Blog 3/09/2025, aprobado Blog 30/12/2025; LOAd70 (Lokon Pharma AB), Blog 3/02/2025(Ter viral onc); LP-184 (Irofulven second generation, Lantern
Pharma)(Alquilantes)), Blog 3/06/2025; LTZ-301 (LTZ
Therapeutics) (Inmunomoduladores),
Blog 3/03/2025; Lurbinectedina (Zepzelca, Jazz Pharmaceuticals
/ Pharma Mar; FDA, EMA huérfano)(Otros antineoplásicos) en
combinación con atezolizumab (Tecentriq, Genentech; FDA, EMA, España UH), Blog 3/07/2025, aprobado Blog 1/11/2025; Lutecio (Lu-177) edotreotido (ITM Isotope
Technologies Munich SE)(Radiofármacos), Blog 3/12/2025; LYT-200 (PureTech Health
plc.)(AcM galectina), Blog 3/02/2025;
- MB-105 (March Biosciences)(CAR-T cell therapies),
Blog 3/12/2025; MNV-201
(Minovia Therapeutics)(Haematopoietic stem cells therapies), Blog 3/10/2025; MRANK-106 (MindRank)(OtrosInh WEE1/YES1), Blog 3/04/2025; MT-125 (Myosin
Therapeutics)(Myosin heavy chain modulators), Blog 3/11/2025; Muzastotug (ADG126,
Adagene)(Anti CTLA-4) más pembrolizumab (Keytruda, Merck Sharp &
Dohme)(Anti PD-1), Blog 31/12/2025;
- Narsoplimab (OMS721, Omeros Corporation)(Anti
MASP-2), Blog 3/06/2025; NG-350A (Akamis Bio), Blog 3/11/2025; Nilotinib (XS003, Xspray Pharma), Blog
3/11/2025; alfa (Anktiva, ImmunityBio) y CAR-NK, Blogs: 4/05/2025, 3/03/2025; Nivolumab (Opdivo, Bristol
Myers Squibb) en combinación con doxorubicina (Adriamycin), vinblastina,
y dacarbazine, Blog 31/12/2025; Nivolumab (Opdivo, Bristol
Myers Squibb) e ipilimumab (Yervoy,
Bristol Myers Squibb), Blog 3/03/2025, aprobado
Blog 1/05/2025; Nogapendequina alfa inbakicept (Nogapendekin alfa,
Anktiva, ImmunityBio, Inc.) más BCG, Blog 3/06/2025; NXC-201 (Immix Biopharma,
Inc.)(CarTAnti BCMA), Blog 3/03/2025;
- OBI-902 (OBI Pharma.), Blog 3/06/2025; Odronextamab (Regeneron
Pharmaceuticals)(AcMB CD20/CD3), Blog 3/03/2025; Olomorasib (Eli Lilly) con pembrolizumab
(Keytruda), Blog 3/10/2025; Orca-T
(Orca Bio), Blog 3/11/2025; OST-HER2 (ADXS 31164, OS
Therapies)(12. Vacunas), Blog 3/07/2025;
- Paige PanCancer Detect (Paige)(Test Diagn), Blog
4/05/2025; Pamlectabart
tismanitina (HDP-101, Heidelberg Pharma), Blog 3/11/2025; Patritumab deruxtecan
(HER3-DXd, Merck)(ADCanti HER3), Blog 3/06/2025; Pembrolizumab (Keytruda, Merck Sharp
& Dohme), Blog 3/03/2025, aprobado Blog 1/07/2025; Petosemtamab (Merus N.V.)(AcMB EGFR/LGR5) más
pembrolizumab (Keytruda, Merck), Blog 3/03/2025; PHOX2B peptide-centric (PC)-CAR T therapy (Myrio
Therapeutics) (Terapia células T con CAR), Blog 3/07/2025; PHST001 (Pheast Therapeutics)(AcM CD24), Blog 3/07/2025; Piflufolastat F 18 (Pylarify), Blog 3/09/2025; Polietilen glicol
sistema embólico de hidrogel (Embrace Hydrogel Embolic System, Instylla Inc.),
Blog 3/09/2025; PQ203
(ProteinQure), Blog 3/09/2025; PYX-201 (Pyxis Oncology, Inc.)(ADCanti dominio extra B fibronectina), Blog
3/03/2025;
- RAD101 (Radiopharm Theranostics)(Radiofarmaco),
Blog 3/07/2025; Raludotatug
deruxtecan (R-DXd; Merck), Blog 3/10/2025; REC-4539
(Recursion)(17.OtrosInh LSD1), Blog 3/02/2025; Relacorilant (Corcept Therapeutics) en combinación
con nab-paclitaxel (Abraxane, Bristol-Myers
Squibb), Blogs Blog 3/10/2025, 3/08/2025; Revumenib (Revuforj, Syndax
Pharmaceuticals; FDA)(9.Inh Menina), Blog 3/07/2025, aprobado Blog 1/11/2025; Rinatabart sesutecan (Rina-S; Genmab), Blog 3/09/2025; RV-01 (Betabart, Radiopharm Theranostics), Blog
3/08/2025;
- Serial CTRS (Onc.AI.)(IA), Blog
3/03/2025; Sevabertinib (Hyrnuo, Bayer HealthCare Pharmaceuticals
Inc.)(1.1.a.Inh HER2), Blog 3/06/2025, aprobadoBlog 1/12/2025; SGR-1505 (Schrödinger Inc.)(Inh MALT1), Blog
3/07/2025; SonoClear System (SonoClear
AS), Blog 3/08/2025; Sonrotoclax (BeOne Medicines), Blog 3/12/2025, 3/11/2025; ST-001 (SciTech Development, Inc.)(), Blog
4/05/2025; Sunvozertinib
(Zegfrovy, Dizal
(Jiangsu) Pharmaceutical Co., Ltd.)(1.1.Inh EGFR/HER2), Blog 3/02/2025, aprobado Blog 1/08/2025;
- Tablecleucel (tab-cel, Ebvallo, Atara Biotherapeutics/Pierre Fabre Pharmaceuticals)(alogT-cell terapia),
Blogs: 3/08/2025, 3/06/2025; TAR-200
(Johnson & Johnson), Blog 3/08/2025; Teclistamab (Tecvayli, Janssen
Biotech, Inc.; FDA (-cqyv), EMA, España UH)(AcMB BCMA/CD3) más daratumumab y
hialuronidasa (subcutaneo; Darzalex Faspro, Janssen Biotech, Inc.; FDA
(-fihj)), Blog 31/12/2025; TGW101 (Tagworks
Pharmaceuticals BV)(ADCanti TAG-72), Blog 4/05/2025; TLX250-CDx (Zircaix, Telix
Pharmaceuticals)(Radiofármaco), Blog 3/03/2025; TOBY Test (TOBY Inc.), Blog
3/08/2025; TT125-802
(Tolremo Therapeutics), Blog 3/09/2025; Trastuzumab deruxtecan (Enhertu,
Daiichi Sankyo; FDA (fam-, -nxki), EMA, España UH)(ADCanti HER2), Blogs: 31/12/2025, 3/11/2025, 3/10/2025; Trastuzumab deruxtecan (Enhertu; Daiichi Sankyo;
FDA (fam- -nxki), EMA, España UH)(ADCanti HER2) y pertuzumab (Perjeta, AstraZeneca; FDA), Blog
3/08/2025, aprobado Blog 30/12/2025; TYRA-300 (Tyra
Biosciences)(1.2.a.Inh FGFR), Blog 3/02/2025;
- UB-VV111 (Umoja Biopharma), Blog 3/10/2025;
- Vepdegestrant (ARV-471, Arvinas and Pfizer)(Antg
Hormonales), Blogs: 3/10/2025, 3/09/2025, 3/07/2025; VS-7375 (Verastem Oncology)(5.Inh KRAS/G12C), Blog
4/05/2025; Vusolimogén
oderparepvec (RP1, Replimune Group, Inc.)(Ter viral onc) combinado con nivolumab
(Opdivo, Bristol Myers Squibb), Blog 3/02/2025;
- Zenocutuzumab (Bizengri, Merus NV; FDA (-zbco), EMA Plan de Investigación Pediátrica), Blog 3/11/2025; Zidesamtinib (Nuvalent), Blog 3/12/2025: Ziftomenib (Komzifti, Kura Oncology)(9.Inh Menina), Blogs: 3/07/2025, 4/05/2025, aprobado Blog 1/12/2025; Zongertinib (Hernexeos, Boehringer Ingelheim)(1.1.a.Inh HER2), Blogs: 3/10/2025, 3/03/2025, aprobado Blog 1/09/2025; Zotiraciclib (TG02, Cothera Bioscience)(3.7.Inh IDH1/2), Blogs: 31/12/2025;
No hay comentarios:
Publicar un comentario